Neovasc

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.

VANCOUVER, March  04, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, recaps the presentation by CEO Fred Colen at the SVB Leerink 9th Annual Global Healthcare Conference on Wednesday, February 26, 2020 in New York City.

Neovasc Updates Investors at SVB Leerink 9th Annual Global Healthcare Conference

VANCOUVER, March  03, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, announced today the Neovasc Reducer™ (the "Reducer") was featured in the peer reviewed publication  EuroIntervention , the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and highlighted in  PCR Online .

Neovasc Reducer Featured in Peer Reviewed EuroIntervention and PCR Online

VANCOUVER and MINNEAPOLIS, Feb.  20, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will request a hearing before the Nasdaq Hearings Panel (the "Panel") as the next step in the process in seeking an extension to satisfy the US$35 million minimum market value of listed securities requirement for continued listing on The Nasdaq Capital Market (the “MVLS Requirement”). On February 19, 2020, the Company received the expected notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff had determined to delist the Company’s common shares from Nasdaq unless the Company requests a hearing before the Panel by February 26, 2020, which the Company will do. This request will ordinarily stay any further action by the Staff and the Company’s securities are expected to continue to be eligible to trade on Nasdaq at least pending the ultimate conclusion of the hearing process.

Neovasc Will Request Nasdaq Hearing After Company Received Expected Delisting Determination From Nasdaq Staff

VANCOUVER, Feb.  18, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Neovasc, Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred Colen, CEO of Neovasc, will be participating in the SVB Leerink 9th Annual Global Healthcare Conference on Wednesday, February 26, 2020 in New York City.  Mr. Colen’s presentation will take place at 3:00 p.m. EST.

Neovasc to Participate in SVB Leerink 9th Annual Global Healthcare Conference on February 26, 2020

VANCOUVER and MINNEAPOLIS, Feb.  12, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today achievement of design freeze for its fully retrievable transfemoral trans-septal Tiara™ (“TF/TS Tiara”) system, including a modified, lower profile valve and a steerable delivery system.

Neovasc Achieves Design Freeze for Transfemoral Trans-septal Tiara™ Mitral Valve System

Medical device maker Neovasc Inc.'s shares NVCN, -7.03% slid more than 7% in premarket trade Tuesday, after the Vancouver-based company said it has launched an independent inquiry into trading of its shares.

Medical device maker Neovasc launches inquiry into trading of its shares for possible market manipulation

Vancouver, Feb.  11, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Neovasc, Inc.  ("Neovasc" or the "Company") ( NASDAQ, TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has retained independent expert Joshua Mitts, a professor at Columbia University specializing in securities trading and the capital markets, to investigate recent past unusual trading activity in the Company’s common shares. 

Neovasc Initiates Independent Inquiry Into Trading of its Shares

VANCOUVER, Feb.  03, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today confirms that the Company fell below the Nasdaq’s minimum market value of listed securities (“MVLS”) threshold of $35 million on January 31, 2020. The MVLS test is based on the closing bid price each day. If the Company maintains an MVLS of at least $35 million for ten consecutive trading days, it will satisfy the MVLS requirement before the Nasdaq grace period ends on February 17, 2020. Today is the last day that a ten consecutive trading day period can begin and be completed before the grace period ends. The Nasdaq has discretion to require satisfaction of the $35 million MVLS requirement for a period in excess of ten consecutive trading days. We will notify the market on or around February 17, 2020 if the Nasdaq uses that discretion or if they notify the Company that it has regained compliance with the MVLS requirement. If the Nasdaq uses that discretion to extend the period in excess of ten days, then the grace period will also be extended and the Company will not be in breach of the MVLS rule during that period if the MVLS remains above $35 million.

Neovasc Provides Update on Nasdaq Compliance

Participating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure

Neovasc Announces Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina

VANCOUVER, Jan.  24, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that after further successful acute animal tests conducted earlier this week, a final design concept for the fully retrievable transfemoral trans-septal Tiara™ (“TF/TS Tiara”) system, including a modified, lower profile valve and a steerable delivery system, has been established and will now move into a design freeze phase review, in accordance with the Company’s quality system.

Neovasc Advances New Transfemoral Trans-septal Tiara Design Concept After Further Successful Tests

VANCOUVER, Jan.  22, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (“Reducer”) was featured in three presentations across Germany this month.

Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations in Germany

Updates on Reducer and Tiara Programs Will be Presented at Advanced Cardiovascular Intervention 2020 Meeting

VANCOUVER, Jan.  15, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE –  Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt of an Administrative Acceptance Review Notification for the Company’s Premarket Approval application (“PMA”) from the U.S. Food and Drug Administration (“FDA”) for its Neovasc Reducer™ (“Reducer”) medical device for the treatment of refractory angina. 

Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer™

VANCOUVER, Jan.  13, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE –  Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, seeks to provide an update for investors, including a recap of recent corporate activity and a look ahead into 2020 in advance of the J.P. Morgan Investor Conference this week.

Neovasc Inc. Investor Update

Avid Bioservices

Endo International

IGM Biosciences Inc

Illumina

IVERIC bio Inc

Kodiak Sciences Inc

Mylan

Pacira Pharmaceuticals

Pfizer

X4 Pharmaceuticals Inc

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfolio.

11 Biotechs and Pharma Stocks Being Given Huge Upside Targets for 2020

Vancouver, Canada, Jan.  06, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules of an aggregate of 1,185,000 series A units ("Series A Units") and 1,241,490 series B units ("Series B Units" and together with the Series A Units, the "Units") at a price of US$4.1351 per Series A Unit and US$4.135 per Series B Unit for aggregate gross proceeds to the Company of approximately US$10 million, before deducting placement agent’s fees and estimated expenses of the Offering payable by the Company.

Neovasc Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market

Vancouver, Canada, Jan.  02, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain institutional investors for the sale of an aggregate of 2,418,322 series A units (“Series A Units”) and series B units (“Series B Units” and together with the Series A Units, the “Units”) at a price of US$4.1351 per Series A Unit and US$4.135 per Series B Unit in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules for aggregate gross proceeds to the Company of approximately US$10 million, before deducting placement  agent’s fees and estimated expenses of the Offering payable by the Company.  The Offering is expected to close on or about January 6, 2020, subject to customary closing conditions.

Neovasc Announces $10 Million Registered Direct Offering Priced At-The-Market

Neovasc (NVCN) news for Tuesday about the company submitting a PMA to the U.S. Food and Drug Administration has NVCN stock soaring.

Neovasc News: NVCN Stock Skyrockets 65% on Angina Treatment Application

Neovasc Inc. (NASDAQ: NVCN) shares are trading sharply higher Tuesday after the company announced it had submitted a premarket approval application to the U.S.

Neovasc Higher By 160% After Submitting Approval Application For Neovasc Reducer

Shares of Neovasc Inc. NVCN, +8.56% shot up 79% in premarket trading Tuesday, after the medical device company said it submitted a premarket approval application (PMA) for its Neovasc Reducer, for the treatment of refactory angina.

Neovasc's stock shoots higher after submission of PMA for angina treatment

VANCOUVER, Dec.  31, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the submission of a Premarket Approval application (“PMA”) to the U.S. Food and Drug Administration (“FDA”) for its Neovasc Reducer™ (“Reducer”) medical device for the treatment of refractory angina. The submission also includes a request for an Advisory Panel meeting.

Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer™

VANCOUVER, Dec.  17, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the “Reducer”) was featured in a special issue titled: “The Future of Medicine” of National Graphic Magazine, published in December 2019. An image of the Reducer was accompanied by a case study of a patient who was implanted with the Reducer. Neovasc’s Medical Director, Prof. Shmuel Banai, MD, Director of the Division of Cardiology and the Head of Interventional Cardiology at the Tel Aviv Medical Center, Tel Aviv, Israel, is also prominently featured.

Neovasc Reducer™ Featured In National Geographic Magazine

VANCOUVER, Dec.  04, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN): NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has been selected as a finalist in this year’s Fierce Innovation Awards – LifeSciences Edition, a peer reviewed awards program from the publisher of FierceBiotech and FiercePharma. The competition highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharma companies. Neovasc was recognized as a finalist in the category of Medical Device Innovation. 

Neovasc Named Finalist in Questex’s Fierce Innovation Awards LifeSciences Edition 2019

VANCOUVER, CA, and BERLIN, DE, Nov.  26, 2019  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured in a supplement in the FOCUS Magazine, one of the three most widely circulated weekly news magazines in Germany. Professor Tommaso Gori, who leads the cardiac catheterization lab at the prestigious University Hospital Mainz, explained to FOCUS readers in the supplement called “Medizinischer Fortschritt” how Reducer therapy helps patients with Chronic Angina Pectoris. Professor Gori commented on the available robust clinical evidence on the safety and efficacy of the Reducer therapy and highlighted that 75% of patients treated with Reducer feel better and experience less chest pain.

Neovasc Reducer™ Featured In FOCUS Magazine

- Educational events featuring the Reducer hosted in Germany and Italy -

News for Neovasc Stock (NVCN)